1.5 Efficacy and Safety of Dulaglutide vs. Metformin in Type 2 Diabetes (AWARD-3) (69-OR)

被引：0
|
作者：
Guillermo E. Umpierrez
Federico P. Manghi
Santiago Tofe Povedano
Linda Shurzinske
Valeria Pechtner
机构：
来源：
Nederlands Tijdschrift voor Diabetologie | 2013年 / 11卷 / 3期
关键词：
D O I：
10.1007/s12467-013-0030-x
中图分类号：
学科分类号：
摘要：
This Phase 3, randomized, double-blind, parallel-arm, monotherapy study compared the efficacy and safety of 2 doses of dulaglutide (DU), a long-acting GLP-1-receptor agonist, to metformin (MET) in patients with early type 2 diabetes (mean 2.6 years) treated with diet and exercise alone or in combination with 1 oral antidiabetic medication (low dose for ≥ 3 months before screening).
引用
收藏
页码：78 / 78
相关论文
共 50 条
  • [21] Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
    Jendle, Johan
    Grunberger, George
    Blevins, Thomas
    Giorgino, Francesco
    Hietpas, Ryan T.
    Botros, Fady T.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2016, 32 (08) : 776 - 790
  • [22] Efficacy and Safety of Once-Weekly Dulaglutide vs. Once-Daily Liraglutide in Japanese Patients with Type 2 Diabetes
    Takamura, Toshinari
    Miyagawa, Jun-Ichiro
    Odawara, Masato
    Takita, Yasushi
    Iwamoto, Noriyuki
    Imaoka, Takeshi
    DIABETES, 2015, 64 : A285 - A285
  • [23] Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes
    Hwang, Y. -C.
    Kang, M.
    Ahn, C. W.
    Park, J. S.
    Baik, S. H.
    Chung, D. J.
    Jang, H. C.
    Kim, K. -A.
    Lee, I. -K.
    Min, K. W.
    Nam, M.
    Park, T. S.
    Son, S. M.
    Sung, Y. -A.
    Woo, J. -T.
    Park, K. S.
    Lee, M. -K.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2013, 67 (03) : 236 - 243
  • [24] Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials
    Reaney, M.
    Yu, M.
    Lakshmanan, M.
    Pechtner, V.
    van Brunt, K.
    DIABETES OBESITY & METABOLISM, 2015, 17 (09): : 896 - 903
  • [25] Retrospective Chart Review of Children With Type 2 Diabetes Mellitus Evaluating the Efficacy of Metformin vs. Insulin vs. Combination Insulin/Metformin
    Meyer, Stacy L.
    Hoffman, Robert P.
    SOUTHERN MEDICAL JOURNAL, 2011, 104 (10) : 684 - 688
  • [26] Cost-Effectiveness of Once-Weekly Semaglutide 1.0 mg vs. Dulaglutide 1.5 mg as Add-On to Metformin in the Treatment of Type 2 Diabetes in Canada
    Johansen, Pierre
    Hakan-Bloch, Jonas
    Liu, Aiden R.
    Persson, Sofie
    Grip, Emilie Toresson
    DIABETES, 2018, 67
  • [27] Efficacy and safety of once weekly dulaglutide versus once daily liraglutide in type 2 diabetes (AWARD6)
    Tofe Povedano, S.
    Dungan, K. M.
    Forst, T.
    Gonzalez Gonzalez, J. G.
    Atisso, C.
    Sealls, W.
    Fahrbach, J. L.
    DIABETOLOGIA, 2014, 57 : S23 - S23
  • [28] 1.2 Efficacy and Safety of Dulaglutide versus Placebo and Exenatide in Type 2 Diabetes (AWARD-1) (66-OR)
    Carol H. Wysham
    Thomas C. Blevins
    Richard Arakaki
    Gildred Colon
    Pedro Garcia
    Charles Atisso
    Debra Kuhstoss
    Jamie Scism-Bacon
    Mark Lakshmanan
    Nederlands Tijdschrift voor Diabetologie, 2013, 11 (3) : 75 - 76
  • [29] RETROSPECTIVE CHART REVIEW OF CHILDREN WITH TYPE 2 DIABETES MELLITUS EVALUATING THE EFFICACY OF METFORMIN VS. INSULIN VS. COMBINATION INSULIN/METFORMIN THERAPY
    Meyer, S. L.
    Hoffman, R. P.
    PEDIATRIC RESEARCH, 2010, 68 (04) : 364 - 364
  • [30] Type 2 diabetes and CKD: safety of metformin vs sulfonylureas
    Reactions Weekly, 2020, 1787 (1) : 12 - 12
12345